Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Generic Firms Get Supreme Shield From Product Liability, But Court Hints At Reg Change

This article was originally published in The Pink Sheet Daily

Executive Summary

In Pliva v. Mensing, the high court said it was impossible for generic manufacturers to comply with both state tort laws and FDA regulations requiring them to have the same labels as those for brand name counterparts.

You may also be interested in...



Brand-Name Drug Makers' Duty To Warn Extends After Product Sale To Another Company

California Supreme Court finds Novartis liable for alleged injuries from use of a generic version of Brethine even though they occurred six years after Novartis transferred the NDA; dissenting opinion says this will expose companies to "liability in perpetuity."

Brand-Name Drug Makers' Duty To Warn Extends After Product Sale To Another Company

California Supreme Court finds Novartis liable for alleged injuries from use of a generic version of Brethine even though they occurred six years after Novartis transferred the NDA; dissenting opinion says this will expose companies to "liability in perpetuity."

FDA Label Decisions On Paxil Don't Deter Verdict Against GSK In Suicide Case

Chicago jury finds GSK failed to adequately warn about risk of suicidal behavior in patients over age 24 taking paroxetine; GSK argued that FDA had found no increased risk in this population.

Related Content

Topics

UsernamePublicRestriction

Register

PS078529

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel